PMID: 9548610Apr 21, 1998Paper

Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases?

Seminars in Surgical Oncology
A L VahrmeijerC J van de Velde

Abstract

The prognosis of patients with irresectable liver metastases derived from colorectal cancer is invariably poor; unfortunately, these tumours show only minor responses to conventional anticancer agents. The best responses have been obtained by fluoropyrimidines delivered as continuous infusion into the hepatic artery (HAI): their rapid uptake and detoxification by liver cells results in relatively low systemic drugs levels. This approach increases mean survival duration from 17 to 26 months and, in few patients, causes "down-staging" that may result in resectability. To improve opportunities for chemotherapy, the technique of 1-hour recirculating perfusion of the vascularly isolated liver (isolated hepatic perfusion, IHP) was developed. If leakage to the systemic circulation is negligible-and the compounds used do not readily cause hepatotoxicity-IHP allows usage of drug doses that would be fatal if delivered systemically. Because alkylating agents generally have steep dose-response curves, mitomycin C (MMC) and melphalan (L-PAM) entered phase I/II studies on IHP. Using these drugs, IHP was performed in principle as a single procedure in 60 otherwise untreated patients at our institution. However, despite preliminary data that i...Continue Reading

References

Jun 1, 1979·The British Journal of Surgery·J M Northover, J Terblanche
Jul 1, 1991·Immunology Today·C T Chu, S V Pizzo
Jun 1, 1990·Immunology Today·S J Russell
Nov 1, 1990·The British Journal of Surgery·J ScheeleA Altendorf-Hofmann
Jan 1, 1987·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·R D RuniaC J van de Velde
Dec 1, 1986·The Journal of Surgical Research·C J van de VeldeA Zwaveling
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L VahrmeijerC J van de Velde
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N E Kemeny
Mar 6, 1996·Journal of the National Cancer Institute·UNKNOWN Meta-Analysis Group in CancerE Levy
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A BridgewaterM K Collins
Oct 1, 1996·Japanese Journal of Clinical Oncology·A MarinelliC J van de Velde
Jun 1, 1996·Immunology Today·D MännelM Clauss
Nov 1, 1996·Current Opinion in Oncology·B M DavisS L Gerson
Jan 1, 1997·Journal of the National Cancer Institute·J A Roth, R J Cristiano
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A F SobreroJ R Bertino
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y M RustumS Seeber
Jan 1, 1997·Immunology Today·P MusianiG Forni

❮ Previous
Next ❯

Citations

Aug 26, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H L McLeodJ Cassidy
Apr 22, 2011·Expert Opinion on Drug Delivery·Oliver Dudeck, Jens Ricke
Jan 25, 2000·Cancer Treatment Reviews·A J BremersC J van de Velde
May 15, 2002·The Cancer Journal·Nancy M Carroll, H Richard Alexander
May 10, 2018·Nanoscale Research Letters·Michael Zhao, Mingyao Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

The Cancer Journal
Margaret K Callahan, N Kemeny
Advances in Experimental Medicine and Biology
Jeffrey M FarmaH R Alexander
Seminars in Surgical Oncology
E J Rutgers, H L Peterse
Clinical Privilege White Paper
© 2022 Meta ULC. All rights reserved